Market Intelligence, Clinical Progress, and High-Purity Reagents for Lymphoma, Autoimmune, and Neuroinflammatory Disease Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for MALT1 drug discovery. MALT1 (Mucosa-Associated Lymphoid Tissue Lymphoma Translocation Protein 1) is a critical cysteine protease (paracaspase) and scaffold protein within the CBM (CARD11-BCL10-MALT1) signalosome. It contains a Death domain and two Ig-like C2-type domains (1 and 2) as per UniProt Q9UDY8. Key clinically relevant mutations include IMD12 (dbSNP:rs398123058) and dbSNP:rs35533328. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | MALT1 Full-Length, Protease Domain, and Paracaspase Domain Recombinant Proteins High purity (>95%), Endotoxin <1EU/ug, Sequence Verified, HEK293 Expressed. |
View MALT1 Products |
| Gene Delivery | MALT1 Promise-ORF / Lentivirus Full-length ORF for stable cell lines. CMV promoter. |
View MALT1 Products |
| Benchmark Ab / Control | Anti-MALT1 Recombinant Antibody (Research Grade) & Control Small Molecule Positive controls for Western/IP and enzymatic assays. |
View MALT1 Products |
| Validator | MALT1 siRNA Set For knockdown verification. Sequence-verified targeting catalytic domain. |
View MALT1 Products |
| Negative Control Mutant | MALT1 C464A (Catalytically Inactive) Negative control for enzymatic assays. Theoretical MW verified. |
View MALT1 Products |
| Related Target A | BTK Synergistic pathway in B-cell receptor signaling. |
View BTK Products |
| Related Target B | BCL10 Direct binding partner in the CBM complex. |
View BCL10 Products |
| Related Target C | CARD11 CBM complex upstream adaptor; oncogenic driver in ABC-DLBCL. |
View CARD11 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| High-Quality Protein for SPR/Binding | High Purity (>95%), Sequence Verified, Theoretical MW confirmed. Full-length & Isolated Protease Domain available. |
| Screening Allosteric vs Active-site Binders | Specific domain truncations available, HEK293 Expressed (Native Glycosylation if applicable). |
| Protease vs Scaffolding Selectivity | Full-length MALT1 with intact binding domains vs isolated Paracaspase domain for differential inhibition assays. |
| Allosteric Resistance Mutation Screening | MALT1 Mutant Recombinant Proteins (key allosteric site variants); Sequence Verified by Mass Spec. |
| Subfamily Off-Target Counter-Screen | Human/Mouse/Cyno MALT1 orthologs plus CASP8, Caspase-3, -7, -8 recombinant proteins for selectivity panels. |
| CBM Complex Assembly Verification | Co-reagents CARD11 & BCL10 proteins available for trimeric pulldown assays. |
| Lack of Cellular Models | MALT1 Lentivirus for stable cell line generation; Premade lentivirus for NF-κB reporter assays. |
| Target Specificity | Validated siRNA included for off-target checks. |
Live MALT1 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for MALT1 therapeutics is intensifying. The therapeutic landscape is rapidly expanding from hematological oncology (ABC-DLBCL, MALT lymphoma) into autoimmune (rheumatoid arthritis, multiple sclerosis) and neuroinflammatory indications. As first-generation allosteric small molecules enter the clinic, major players (BioNTech, Novartis, Roche/Genentech, ONO Pharma) are focusing heavily on highly selective paracaspase inhibitors that spare essential scaffolding functions. The next wave includes emerging PROTAC degraders, covalent inhibitors, and brain-penetrant inhibitors for CNS indications. First-generation therapies targeting the BCR pathway (e.g., BTK inhibitors) face resistance in ABC-DLBCL, positioning MALT1 as a critical downstream node. Combination strategies (MALT1i + BTKi / BCL2i) are expected to become standard of care.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule (Allosteric) | BioNTech (ex-Bayer), Novartis, ONO Pharma, Sanofi | ABC-DLBCL, MALT Lymphoma, Autoimmune | Enzymatic Selectivity Assay (need high-purity recombinant domains, caspase-free proteins) |
| PROTAC / Degrader | Biotech Innovators, Academic Consortia | Refractory Lymphoma | Ternary Complex Assays (need full-length MALT1 + E3 ligase, structural fidelity) |
| Covalent Inhibitor | Roche/Genentech | Autoimmune Diseases | Target Engagement Assay (need C464A mutant as negative control) |
| Small Molecule (Active Site) | Various | Solid Tumors / Lymphoma | Selectivity Screening (need Sequence Verified targets) |
| Scaffolding Disruptor (Peptide/Protein) | Early Discovery Labs | Autoimmune Disease | CBM Complex Pulldown (need CARD11/BCL10/MALT1 trimer reagents) |
| Brain-Penetrant | Emerging Biotech | Multiple Sclerosis | Cell-based NF-κB Reporter (need lentivirus-stable cell lines) |
Scientific Insights: Functional Domains and Mutations
MALT1 (UniProt Q9UDY8) possesses three key domains: a Death domain (involved in protein-protein interactions), and two Ig-like C2-type domains (1 and 2) that contribute to substrate recognition and scaffold function. The paracaspase domain (Cys464 active site) mediates proteolytic activity. Clinically relevant mutations include IMD12 (rs398123058), which causes combined immunodeficiency, and rs35533328, a common variant. These mutations underscore the need for selective inhibitors that avoid interfering with non-proteolytic functions.